Biogen Has Agreed To Acquire Human Immunology Biosciences For $1.15B Upfront And Up To $650M In Potential Milestone Payments
Biogen Has Agreed To Acquire Human Immunology Biosciences For $1.15B Upfront And Up To $650M In Potential Milestone Payments
Biogen已同意以11.5亿美元的预付金和高达6.5亿美元的潜在里程碑付款收购人类免疫学生物科学
- Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseases
- Felzartamab is an investigational anti-CD38 monoclonal antibody that, through its cell depletion approach, has demonstrated clinical proof of concept in rare immune-mediated indications, with plans to advance to Phase 3
- Proposed acquisition builds on Biogen capabilities in immunology with plans to combine Human Immunology Biosciences expertise in immune-mediated indications with Biogen's global development and commercial experience in rare diseases
- 该交易将包括费尔扎他单抗，这是一种潜在的同类首创候选治疗药物，有望成为一系列免疫介导疾病的管道产品
- Felzartamab是一种在研的抗CD38单克隆抗体，通过其细胞耗尽方法，已在罕见的免疫介导适应症中证明了临床概念的证实，并计划进入3期
- 拟议的收购建立在Biogen在免疫学领域的能力基础上，并计划将人类免疫学生物科学在免疫介导适应症方面的专业知识与Biogen在罕见疾病领域的全球开发和商业经验相结合